Apnimed Reports $193.7M Net Income Turnaround and IPO Completion

Apnimed, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company achieved a net income of $193.7 million, a substantial turnaround from a net loss of $98.1 million in the same period last year. This improvement was primarily driven by a one-time gain of $85.4 million from the sale of its equity method investment in Shionogi-Apnimed Sleep Science, LLC (SASS) and a gain of $57.1 million from the reversal of a deposit liability. Revenue from related parties also increased to $96.9 million, up from $20.2 million in the prior year, reflecting a significant rise in research and development services provided to SASS.

Operating expenses for the six months ended June 30, 2026, totaled $40.6 million, a decrease of 24% compared to $53.3 million in the same period of 2025. This decline was largely attributed to a 54% reduction in research and development expenses, which fell to $18.0 million from $39.4 million, as the company completed its Phase 3 clinical trials for its lead product candidate, Oxnimbi. General and administrative expenses, however, rose by 77% to $19.2 million, driven by increased legal and consulting fees as well as costs associated with preparing for commercialization.

In terms of strategic developments, Apnimed completed the SASS Disposition in April 2026, selling its 50% interest in the joint venture to Shionogi for $100 million, with potential additional milestone payments. The company also successfully completed its initial public offering (IPO) in August 2026, raising approximately $200.4 million in net proceeds. This IPO included the automatic conversion of all outstanding convertible preferred stock and Class B and C common stock into Class A common stock, significantly altering the company’s capital structure.

Operationally, Apnimed reported a cash balance of $172.8 million as of June 30, 2026, a notable increase from $41.9 million at the end of 2025. The company anticipates that its existing cash, combined with the proceeds from the IPO, will be sufficient to fund operations through mid-2028. However, it continues to face risks associated with the commercialization of Oxnimbi, which is pending FDA approval, and the need for additional funding to support ongoing research and development activities.

Looking ahead, Apnimed remains focused on advancing Oxnimbi through the regulatory process and preparing for its potential commercialization. The company acknowledges the inherent uncertainties in clinical development and the need for substantial additional funding to support its growth strategy. As it navigates these challenges, Apnimed aims to leverage its recent financial successes to enhance its operational capabilities and market presence in the pharmaceutical industry.